Cadence Design Systems, Inc (CDNS - Free Report) is teaming up with the Antiviral Platform (“ASAP”) Discovery Consortium to develop antivirals to prevent pandemics in the future. CDNS will offer its OpenEye molecular design software to drive the artificial intelligence (AI)-driven structure-enabled ASAP platform.
The goal of the AI-driven ASAP Discovery Consortium is to fast-track structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics equitably and affordably across the globe.
The ASAP Discovery Consortium is an Antiviral Drug Discovery U19 Center for Pathogens of Pandemic Concern. It is funded by the National Institute of Allergy and Infectious Diseases, which is a part of the National Institutes of Health, through a $68 million funding as part of the Antiviral Program for Pandemics.
The ASAP Discovery Consortium boasts partners like the Stanford University School of Medicine, Diamond Light Source, the Weizmann Institute of Science, Medchemica, Mount Sinai and the Fred Hutchinson Cancer Center. It also has a worldwide network of scientists and industry collaborators.
OpenEye’s software will help scientists develop therapeutics for less-researched infectious diseases. OpenEye’s various applications, toolkits and Orion platform will assist computational chemists in creating a strong antiviral drug discovery pipeline by leveraging structural biology, AI, machine learning (“ML”) technology and computational chemistry.
Cadence acquired OpenEye Scientific Software for about $500 million in cash in September 2022. With OpenEye’s acquisition, pharmaceutical and biotechnology companies will be able to work on robust drug discovery solutions by combining OpenEye’s molecular modeling and simulation software solutions with Cadence’s algorithmic and solver expertise, data management infrastructure, as well as innovative AI/ML and cloud solutions.
CDNS currently carries a Zacks Rank #3 (Hold). In the past year, the stock has gained 59.7% compared with the Zacks sub-industry’s growth of 46.5%.
Stocks to Consider
Some better-ranked stocks worth consideration in the broader technology space are Blackbaud (BLKB - Free Report) , BlackBerry (BB - Free Report) and Woodward (WWD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Blackbaud’s 2023 EPS improved 1.8% in the past 60 days to $3.86. BLKB’s long-term earnings growth rate is 23.4%.
Blackbaud’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 10.6%. Shares of BLKB have surged 49.3% in the past year.
The Zacks Consensus Estimate for BlackBerry’s fiscal 2024 EPS has remained unchanged in the past 30 days at 4 cents. BB’s earnings outpaced the Zacks Consensus Estimate in three of the last four quarters, the average surprise being 55%. Shares of BB have lost 7.4% in the past year.
The Zacks Consensus Estimate for Woodward’s fiscal 2024 EPS has improved 6.9% in the past 60 days to $4.92.
WWD’s earnings outpaced the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.7%. Shares of WWD have jumped 39.2% in the past year.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Cadence Design Systems, Inc (CDNS - Free Report) is teaming up with the Antiviral Platform (“ASAP”) Discovery Consortium to develop antivirals to prevent pandemics in the future. CDNS will offer its OpenEye molecular design software to drive the artificial intelligence (AI)-driven structure-enabled ASAP platform.
The goal of the AI-driven ASAP Discovery Consortium is to fast-track structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics equitably and affordably across the globe.
The ASAP Discovery Consortium is an Antiviral Drug Discovery U19 Center for Pathogens of Pandemic Concern. It is funded by the National Institute of Allergy and Infectious Diseases, which is a part of the National Institutes of Health, through a $68 million funding as part of the Antiviral Program for Pandemics.
The ASAP Discovery Consortium boasts partners like the Stanford University School of Medicine, Diamond Light Source, the Weizmann Institute of Science, Medchemica, Mount Sinai and the Fred Hutchinson Cancer Center. It also has a worldwide network of scientists and industry collaborators.
OpenEye’s software will help scientists develop therapeutics for less-researched infectious diseases. OpenEye’s various applications, toolkits and Orion platform will assist computational chemists in creating a strong antiviral drug discovery pipeline by leveraging structural biology, AI, machine learning (“ML”) technology and computational chemistry.
Cadence acquired OpenEye Scientific Software for about $500 million in cash in September 2022. With OpenEye’s acquisition, pharmaceutical and biotechnology companies will be able to work on robust drug discovery solutions by combining OpenEye’s molecular modeling and simulation software solutions with Cadence’s algorithmic and solver expertise, data management infrastructure, as well as innovative AI/ML and cloud solutions.
CDNS currently carries a Zacks Rank #3 (Hold). In the past year, the stock has gained 59.7% compared with the Zacks sub-industry’s growth of 46.5%.
Stocks to Consider
Some better-ranked stocks worth consideration in the broader technology space are Blackbaud (BLKB - Free Report) , BlackBerry (BB - Free Report) and Woodward (WWD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Blackbaud’s 2023 EPS improved 1.8% in the past 60 days to $3.86. BLKB’s long-term earnings growth rate is 23.4%.
Blackbaud’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 10.6%. Shares of BLKB have surged 49.3% in the past year.
The Zacks Consensus Estimate for BlackBerry’s fiscal 2024 EPS has remained unchanged in the past 30 days at 4 cents. BB’s earnings outpaced the Zacks Consensus Estimate in three of the last four quarters, the average surprise being 55%. Shares of BB have lost 7.4% in the past year.
The Zacks Consensus Estimate for Woodward’s fiscal 2024 EPS has improved 6.9% in the past 60 days to $4.92.
WWD’s earnings outpaced the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.7%. Shares of WWD have jumped 39.2% in the past year.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on BLKB - FREE
Get the latest research report on CDNS - FREE
Get the latest research report on WWD - FREE
Get the latest research report on BB - FREE